Barclays
UROV

Barclays’s Urovant Sciences Ltd. UROV Stock Holding History

Barclays’s Portfolio UROV Stock Details UROV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-149
Closed -$1K – 7071
2019
Q3 		$1K Buy
+149
New +$1.29K ﹤0.01% 6640
2019
Q1 		– Sell
-5,627
Closed -$37K – 7488
2018
Q4 		$37K Buy
+5,627
New +$51.2K ﹤0.01% 5635

Other funds holding UROV

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Barclays's UROV Position: Q4 2019 in Review

Barclays sold out of Urovant Sciences Ltd. (UROV) in Q4 2019, closing a stake of 149 shares — an estimated $1K sold.

Barclays first reported a position in UROV in Q4 2018 and held it in 2 quarters. The position peaked at $37K in Q4 2018. 25 funds tracked by Wall St. Rank hold UROV as of Q4 2019.

  • Barclays reported no remaining Urovant Sciences Ltd. position as of Q4 2019 after selling out during the quarter.
  • Barclays sold 149 Urovant Sciences Ltd. shares in Q4 2019, an estimated $1K.
  • Barclays first reported a position in Urovant Sciences Ltd. in Q4 2018 and held it in 2 quarters.
  • Barclays's Urovant Sciences Ltd. position peaked at $37K in Q4 2018.
  • 25 funds tracked by Wall St. Rank held Urovant Sciences Ltd. as of Q4 2019.

Based on Barclays's 13F filing for Q4 2019, filed 10 Feb 2020.